
FDA Delivers a CRL to Glofitamab for Relapsed/Refractory DLBCL
Additional reporting by Laura Joszt, MA. The FDA has issued a complete response letter (CRL) to the combination of glofitamab-gxbm (Columvi; Genentech) plus gemcitabine and oxaliplatin (GemOx) for the treatment of relapsed or refractory diffuse large B- …